Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice.
Using the phage lambdaLIZ-based transgenic in vivo mutagenesis assay, the mean mutant frequencies in the target gene, lacI, were found to be significantly increased in lymphoid tissues of congenic BALB/c.lambdaLIZ N5 mice in the terminal stage of a plasmacytoma induction experiment, 213-280 days after the first i.p. injection of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane). In plasmacytoma-bearing mice (n = 7), mutant frequencies in the spleens and mesenteric lymph nodes were elevated 2.46-fold and 5.35-fold, respectively, when compared with age-matched controls. In plasmacytoma-negative mice (n = 11), mutant frequencies were increased 2.30-fold (spleens) and 3.48-fold (mesenteric nodes). These results, interpreted in conjunction with our previous findings (K. Felix et al., Cancer Res., 58: 1616-1619, 1998) of approximately 3-fold elevations in pristane-induced splenic mutagenesis on day 42 postpristane, indicate that increased mutant levels in lymphoid tissues persist throughout plasmacytomagenesis in genetically susceptible BALB/c mice.
Felix
K
K
Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA. felixk@dc37a.nci.nih.gov
Kelliher
K A
KA
Bornkamm
G W
GW
Janz
S
S
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D002273:Carcinogens / Q000633:toxicity*; D004247:DNA / Q000235:genetics*; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D029968:Escherichia coli Proteins; D005260:Female; D017930:Genes, Reporter / Q000235:genetics*; D007763:Lac Operon / Q000235:genetics*; D056968:Lac Repressors; D008198:Lymph Nodes / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D008221:Lymphoid Tissue / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016296:Mutagenesis; D010534:Peritoneal Neoplasms / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D010954:Plasmacytoma / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D012097:Repressor Proteins / Q000235:genetics; D013154:Spleen / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D013729:Terpenes / Q000633:toxicity*
D001426:Bacterial Proteins; D002273:Carcinogens; D004273:DNA, Neoplasm; D029968:Escherichia coli Proteins; D056968:Lac Repressors; D012097:Repressor Proteins; D013729:Terpenes; C009042:pristane; D004247:DNA